Clear Harbor Asset Management LLC Sells 6,500 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Clear Harbor Asset Management LLC reduced its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 5.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 109,575 shares of the company’s stock after selling 6,500 shares during the period. Clear Harbor Asset Management LLC’s holdings in Teva Pharmaceutical Industries were worth $2,415,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the stock. Stifel Financial Corp lifted its stake in shares of Teva Pharmaceutical Industries by 54.0% during the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after purchasing an additional 23,283 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after buying an additional 40,218 shares in the last quarter. Sio Capital Management LLC purchased a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $24,314,000. CWA Asset Management Group LLC purchased a new stake in Teva Pharmaceutical Industries during the fourth quarter valued at approximately $3,340,000. Finally, Two Sigma Advisers LP lifted its holdings in shares of Teva Pharmaceutical Industries by 15.3% during the 3rd quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares during the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, Director Roberto Mignone sold 286,000 shares of the firm’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $22.01, for a total transaction of $6,294,860.00. Following the completion of the sale, the director now directly owns 695,000 shares in the company, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Christine Fox sold 19,388 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares in the company, valued at $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.55% of the stock is currently owned by insiders.

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $21.97 on Tuesday. The stock has a 50 day moving average of $19.33 and a two-hundred day moving average of $18.26. Teva Pharmaceutical Industries Limited has a 12 month low of $10.86 and a 12 month high of $22.80. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on TEVA shares. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. JPMorgan Chase & Co. increased their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. Piper Sandler lifted their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday. Finally, Barclays boosted their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday, December 18th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $22.13.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.